MacroGenics, Inc. - Common Stock (MGNX)
Frequently Asked Questions About MacroGenics, Inc. - Common Stock (MGNX)
How can investors keep updated on MacroGenics' progress?
Investors can stay updated on MacroGenics' progress by visiting the company's official website, subscribing to its press releases, and following its financial reports and investor presentations. Additionally, the company often participates in investor conferences and webinars to share insights into its development pipeline and business strategies.
How does MacroGenics address patient needs?
MacroGenics actively engages with patients and healthcare providers to understand their needs and experiences. This feedback informs the company's therapeutic development process, ensuring that the products it develops address real-world challenges faced by patients with cancer and autoimmune diseases.
How does MacroGenics contribute to the community?
MacroGenics is committed to corporate social responsibility and contributes to the community through various philanthropic efforts. The company engages in initiatives that support healthcare, science education, and cancer awareness, ensuring that it plays a positive role in society.
How does MacroGenics ensure its products are safe?
MacroGenics adheres to stringent regulatory guidelines set by health authorities like the FDA to ensure the safety and efficacy of its products. The company conducts extensive preclinical studies followed by phased clinical trials to gather data on safety, dosage, and therapeutic effects before seeking market approval.
Is MacroGenics a publicly traded company?
Yes, MacroGenics, Inc. is publicly traded on the Nasdaq under the ticker symbol MGNX. The company went public in 2013, and being listed on a major stock exchange helps it raise capital to fund its research and development initiatives.
What are the future prospects for MacroGenics?
The future prospects for MacroGenics are promising as the company advances its clinical pipeline and explores new opportunities within the biotechnology space. By focusing on innovative therapies and expanding its research capabilities, MacroGenics aims to make significant contributions to the treatment of cancer and beyond.
What are the main therapeutic areas that MacroGenics focuses on?
MacroGenics primarily focuses on oncology, particularly the development of therapies for various types of cancer. The company is also involved in exploring treatments for autoimmune diseases, leveraging its unique drug development platforms.
What challenges does MacroGenics face?
Like many biotechnology companies, MacroGenics faces challenges such as the high cost and risk associated with drug development, competition from other firms, and the evolving regulatory landscape. The company continually adapts its strategies to navigate these challenges while striving to bring innovative therapies to market.
What does MacroGenics, Inc. do?
MacroGenics, Inc. is a biotechnology company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary DART (Dual-Affinity Re-Targeting) platform to create engineered antibodies that can selectively target and eliminate tumors while minimizing damage to healthy cells.
What financial support has MacroGenics received?
MacroGenics has received funding from various sources, including public offerings, private placements, and grants. This financial support has enabled the company to invest in research and development and expand its product pipeline.
What is the DART platform?
The DART (Dual-Affinity Re-Targeting) platform is MacroGenics' proprietary technology that allows for the design of bispecific antibodies. This platform enables the simultaneous targeting of two distinct antigens, aiming to enhance the therapeutic potential of the antibodies in treating cancer by redirecting immune cells to attack cancer cells specifically.
What is the significance of MacroGenics' stock performance?
The stock performance of MacroGenics, like other biotech companies, is closely tied to its clinical trial results, regulatory approvals, and general market conditions. Significant fluctuations can provide insights into investor sentiment regarding the company's growth potential, pipeline progress, and overall market standing.
What is the status of MacroGenics' clinical trials?
MacroGenics is actively conducting multiple clinical trials to evaluate the safety and efficacy of its product candidates. These trials are crucial for gaining regulatory approval and advancing its therapies towards market availability, with several candidates being tested in various stages of clinical development.
What is the vision of MacroGenics?
MacroGenics envisions a future where targeted therapies revolutionize the treatment of cancer and autoimmune diseases. The company is dedicated to helping patients achieve better outcomes through its innovative therapeutics, while fostering a culture of scientific excellence and collaboration.
What products has MacroGenics developed?
MacroGenics has developed several product candidates, with Margetuximab being one of the lead assets. Margetuximab is a monoclonal antibody designed for the treatment of breast cancer that expresses the HER2 protein. The company is actively working on various other candidates in clinical trials to address unmet medical needs in oncology.
What types of collaborations or partnerships does MacroGenics seek?
MacroGenics seeks collaborations and partnerships with other biotech and pharmaceutical companies, academic institutions, and research organizations. These partnerships facilitate the exchange of knowledge, technology, and resources, accelerating the development of innovative therapies and broadening the impact of its research.
When was MacroGenics founded?
MacroGenics, Inc. was founded in 2000. Since its inception, the company has been committed to advancing the field of targeted therapies to improve patient outcomes in oncology and autoimmune disorders.
Where is MacroGenics, Inc. located?
MacroGenics, Inc. is headquartered in Rockville, Maryland. The location allows the company to be part of a vibrant biotech ecosystem, facilitating collaboration and access to a network of industry experts and resources.
Who is the CEO of MacroGenics?
As of October 2023, the CEO of MacroGenics is Scott Koenig, M.D., Ph.D. Dr. Koenig has a strong background in biotechnology and pharmaceutical research and development, bringing extensive experience to lead the company in its mission to develop cancer therapies.
What is the current price of MacroGenics, Inc. - Common Stock?
The current price of MacroGenics, Inc. - Common Stock is 1.220
When was MacroGenics, Inc. - Common Stock last traded?
The last trade of MacroGenics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of MacroGenics, Inc. - Common Stock?
The market capitalization of MacroGenics, Inc. - Common Stock is 74.55M
How many shares of MacroGenics, Inc. - Common Stock are outstanding?
MacroGenics, Inc. - Common Stock has 61.11M shares outstanding.